Single-dose HPV vaccine schedule advocacy — the WHO SAGE recommendation in April 2022 and subsequent national policy shifts toward one-dose primary series for girls aged 9-14, based on robust immunogenicity and efficacy data from India, Kenya, and Costa Rica trials, representing the fastest-growing policy driver in the global HPV vaccine market — creates the most access-expanding...